<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000310.v1.p1" parentStudy="phs000310.v1.p1" createDate="2010-10-20" modDate="2011-01-27">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Mark A. Rubin</td><td>Weill Cornell Medical College, New York, NY, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Discovery of Non-ETS Gene Fusions using RNA Sequencing</StudyNameEntrez>
	<StudyNameReportPage>Discovery of Non-ETS Gene Fusions in Human Prostate Cancer using Next Generation RNA Sequencing</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Half of prostate cancers harbor gene fusions between <i>TMPRSS2</i> and members of the <i>ETS</i> transcription factor family. To   	date little is known about the presence of non-ETS fusion events in prostate cancer. We employed next-generation transcriptome   	sequencing (RNA-Seq) in order to explore the whole transcriptome of 25 human prostate cancer samples for the presence of chimeric   	fusion transcripts. We generated more than 1 billion sequence reads and used a novel computational approach (FusionSeq) in order   	to identify novel gene fusion candidates with high confidence. In total, we discovered and characterized seven new cancer-specific   	gene fusions, two involving the ETS genes <i>ETV1</i> and <i>ERG</i>, and five involving non-ETS genes such as <i>CDKN1A</i> (p21), <i>CD9</i> and   	<i>IKBKB</i> (IKK-beta), genes known to exhibit key biological roles in cellular homeostasis or assumed to be critical in   	tumorigenesis of other tumor entities, as well as the oncogene PIGU and the tumor suppressor gene <i>RSRC2</i>. The novel gene fusions are   	found to be of low frequency but interestingly, the non-ETS fusions were all present in prostate cancer harboring the <i>TMPRSS2-ERG</i>  	gene fusion. Future work will focus on determining if the ETS rearrangements in prostate cancer are associated or directly   	predispose to a rearrangement prone phenotype.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Prostate tissue was obtained by robotic prostatectomy.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="21036922"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20179022"/>
		</Publication>
		<Publication>
			<Pubmed pmid="11607813"/>
		</Publication>
		<Publication>
			<Pubmed pmid="12403772"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19396168"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20054297"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17567988"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19741701"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15034568"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19407851"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18451133"/>
		</Publication>
		<Publication>
			<Pubmed pmid="8521390"/>
		</Publication>
		<Publication>
			<Pubmed pmid="9736046"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19671767"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20585448"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18245377"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18563191"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17203224"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15671525"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19835606"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19962179"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19136943"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19592507"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19433513"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17361217"/>
		</Publication>
		<Publication>
			<Pubmed pmid="9626469"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19584163"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18487995"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20526349"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16951139"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19034268"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19293179"/>
		</Publication>
		<Publication>
			<Pubmed pmid="14695144"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20233430"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16959974"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20033038"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19360079"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18838613"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20579941"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17671502"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18283340"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16254181"/>
		</Publication>
		<Publication>
			<Pubmed pmid="14518029"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17406028"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17047043"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16467110"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16170348"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18500259"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Prostatic Neoplasms"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Mark A. Rubin</AttName>
			<Institution>Weill Cornell Medical College, New York, NY, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="PPC" longName="For general medical research, for non-profit only "/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>nhgridac@mail.nih.gov</DacEmail>
      <DacPhone></DacPhone>
      <DacFax>301-480-2770</DacFax>
      <DacUrl>http://grants.nih.gov/grants/gwas</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000310.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
               http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000310.v1.p1
            </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000310.v1.p1" FileName="DUC_for_Discovery_of_Non-ETS_Gene_Fusions_in_Human_Prostate_Cancer_using_Next_Generation_RNA_Sequencing.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>For general medical research, for non-profit only </ConsentName>
        <ConsentAbbrev>PPC</ConsentAbbrev>
        <UseLimitation>A prospective study evaluating Health Related Quality of Life (HRQOL) following Robotic Prostatectomy for the treatment of localized prostate Cancer: Comparison with Open Radical Prostatectomy</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
